What Scientists Know About the Risk of Breakthrough Covid Deaths

Deaths among people who have been fully vaccinated remain rare, but older adults and those with compromised immune systems are at much higher risk.
Source: NYT Health - Category: Consumer Health News Authors: Tags: your-feed-science Disease Rates Coronavirus (2019-nCoV) Vaccination and Immunization Cancer Multiple Myeloma Immune System Antibodies Multiple Myeloma Research Foundation Powell, Colin L your-feed-health Source Type: news

Related Links:

The death of Colin Powell, an 84-year-old former four-star general who served as Chairman of the Joint Chiefs of Staff under U.S. President George H.W. Bush and Secretary of State under President George W. Bush and is perhaps best known for his role in bringing the U.S. into its second war in Iraq, is a high-profile reminder of a grim reality: COVID-19 is not just a pandemic of the unvaccinated, as current president Joe Biden likes to say, but a pandemic of the elderly, too. From early on in the pandemic, we’ve known the virus disproportionately kills older people, and the overall data make that pretty clear: About 5...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
CONCLUSIONS: The NOD2 and COX6C genes might be used as prognostic biomarkers in MM. The two genes might be associated with the development of COVID-19 infection.PMID:34623759 | DOI:10.1111/ijlh.13717
Source: International Journal of Laboratory Hematology - Category: Hematology Authors: Source Type: research
CONCLUSION: Most pediatric cancer patients with COVID-19 should have good clinical outcomes except for patients with critical infections. Cancer patients can tolerate chemotherapy including induction phase, alongside COVID-19 treatment. In severe and critical COVID-19, RDV might have a potential benefit.PMID:34420893 | PMC:PMC8312090 | DOI:10.1016/j.clml.2021.07.025
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Source Type: research
This study showed that the leakage of this mitochondrial nucleic material may occur as a result of mitochondrial dysfunction, which may involve genetic mutations in genes encoding mitochondrial proteins or incomplete degradation of mitochondrial dsDNA in the lysosome - which is a 'degradation factory' of the cell. Upon the leakage into the cytoplasm, this undegraded dsDNA is detected by a 'foreign' DNA sensor of the cytoplasm (IFI16) which then triggers the upregulation of mRNAs encoding for inflammatory proteins." Using a PD zebrafish model (gba mutant), the researchers demonstrated that a combination of PD-li...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
In conclusion, PLG attenuates high calcium/phosphate-induced vascular calcification by upregulating P53/PTEN signaling in VSMCs. Tsimane and Moseten Hunter-Gatherers Exhibit Minimal Levels of Atrial Fibrillation https://www.fightaging.org/archives/2021/03/tsimane-and-moseten-hunter-gatherers-exhibit-minimal-levels-of-atrial-fibrillation/ Epidemiological data for the Tsimane and Moseten populations in Bolivia shows that they suffer very little cardiovascular disease in later life, despite a presumably greater lifetime burden of infectious disease (and consequent inflammation) than is the case for people i...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Exp Ther Med. 2021 Apr;21(4):392. doi: 10.3892/etm.2021.9823. Epub 2021 Feb 24.ABSTRACTA continuing outbreak of pneumonia associated with the 2019 novel coronavirus (2019-nCoV) was initially described in Wuhan, China in December 2019. Weak and elderly individuals, and those with chronic diseases such as hematological malignancies are prone to develop severe pneumonia. The humoral immunity of patients with multiple myeloma is prevalently low, and their inferior immunity further deteriorates during chemotherapy. For patients with onco-hematological malignancies infected with 2019-nCoV during the first chemotherapy cycle, the...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Authors: Source Type: research
ConclusionOur case adds important context around treatment choice for MM patients in the era of COVID-19 and whether CAR T therapy can be administered to patients who have recovered from COVID-19. As the COVID-19 global pandemic continues, the decision of whether to proceed with CAR T cell therapy will require extensive discussion weighing the potential risks and benefits of therapy. This case suggests that it is possible to successfully complete anti-BCMA CAR T cell therapy after recovery from COVID-19.CRB-402 study registered 6 September 2017 at clinicaltrials.gov (NCT03274219).
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
Patients to be given treatments less likely to damage immune system and in some cases able to be taken at homeNHS England is spending £160m on new “Covid-friendly” cancer drugs that will be less likely to damage the immune system and, in some cases, can be taken at home so that patients do not have to visit hospital.NHS England said 2,000 patients had already benefitted from a range of treatments approved for use as “swaps” for existing drugs. More will be available from this week, after a series of deals struck between the NHS and pharma companies, it said in a statement.Some of these new opt...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: NHS Cancer Society Health Cancer research Medical research Science UK news Coronavirus outbreak Source Type: news
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today ’s challenges and opportunities. The Catalyst welcomes guest contributors, including patients, stakeholders, innovators and others, to share their perspectives and point of view. Today, we are pleased to welcome a guest post from Chris Arendt, Ph.D., a leader of Takeda’s oncology team to discuss how the company is ensuring cancer research and medicines continue to benefit patients in the age of COVID-19.“The new normal” has been used to describe the challenging and dy...
Source: The Catalyst - Category: Pharmaceuticals Authors: Tags: PhRMA Member Company Cancer Coronavirus Source Type: news
Researchers say selinexor, which is currently approved treat multiple myeloma, blocks a protein that allows coronavirus to multiply in our cells and plays a role in the inflammatory response.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Coronavirus | COVID-19 | Health | Myeloma | Science | Vaccines